Robert Motzer
Motzer, Robert J.
Motzer, Robert J., 19..-....
VIAF ID: 89830268 (Personal)
Permalink: http://viaf.org/viaf/89830268
Preferred Forms
- 200 _ | ‡a Motzer ‡b Robert J.
- 100 1 _ ‡a Motzer, Robert J.
- 100 1 _ ‡a Motzer, Robert J.
- 100 1 _ ‡a Motzer, Robert J.
-
-
- 100 1 _ ‡a Motzer, Robert J., ‡d 19..-....
- 100 0 _ ‡a Robert Motzer
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib | |
Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer | |
Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas | |
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma | |
Phase II trial of irofulven | |
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors | |
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. | |
Phase III Trial of Adjuvant Sunitinib in Patients With High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis | |
Poor-risk testicular cancer and high-dose chemotherapy | |
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor | |
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. | |
Predicting Teratoma in the Retroperitoneum in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection | |
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma | |
Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma. | |
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group | |
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. | |
Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations | |
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma | |
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma | |
Recommendations of follow-up after treatment of germ cell tumors | |
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. | |
Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours | |
Renal cell carcinoma: a priority malignancy for development and study of novel therapies. | |
Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival | |
Renal Cell Carcinoma : Molecular Targets and Clinical Applications | |
Renal cell carcinoma: progress against an elusive tumor | |
Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence | |
Research and innovation in the development of everolimus for oncology. | |
Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors: A 28-Year Experience at Memorial Sloan-Kettering Cancer Center | |
Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials | |
Results of Retroperitoneal Lymph Node Dissection for Clinical Stage I and II Pure Embryonal Carcinoma of the Testis | |
Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome | |
Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma | |
Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum | |
Safety and clinical activity of vascular endothelial growth factor receptor | |
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. | |
Salvage chemotherapy for patients with advanced pure seminoma | |
Sarcomatoid renal cell carcinoma: biology, natural history and management | |
Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. | |
Sequelae of treatment in long-term survivors of testis cancer | |
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. | |
Stage I testicular cancer management and necessity for surgical expertise | |
Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. | |
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients | |
Sunitinib malate for the treatment of solid tumours: a review of current clinical data | |
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma | |
An update in neoplastic diseases, c2002: |